CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← MERCK (MRK) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

MERCK (MRK)

Pharmaceutical Preparations · market cap $364.4B · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-01 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Merck & Co. (MRK) is a top-five global pharma by revenue, generating $65B in 2025 sales with a $305B market cap. The company carries a substantial net debt load of ~$43.8B against $5.3B cash, and its near-term catalyst calendar is anchored by a high-importance Phase 3 SC Tulisokibart readout (Aug 1) and a Phase 3 pembrolizumab data point (Oct 28). Recent Phase 3 results on July 6 were mixed — four positives and two negatives — underscoring the breadth and variability of its pipeline.
The catalyst path
  • 2026-12-01 (est.)Phase 2 · Axatilimabimp 7/10
  • 2026-12-05 (est.)Phase 2 · pembrolizumabimp 7/10
  • 2026-12-11 (est.)Phase 2 · pembrolizumabimp 7/10
  • 2026-12-15 (est.)Phase 2 · Infliximabimp 7/10
  • 2026-12-16 (est.)Phase 2 · pembrolizumabimp 7/10
  • 2026-12-22 (est.)Phase 2 · Belzutifanimp 7/10
  • 2026-12-23 (est.)Phase 2 · Lenvatinibimp 7/10
  • 2026-12-30 (est.)Phase 2 · Belzutifanimp 7/10
Pipeline
AssetPhaseIndication
V114 Non-adjuvantedPhase 2Pneumococcal Infections
LonafarnibPhase 2Breast Cancer
Pemetrexed CisplatinPhase 2Non Small Cell Lung Cancer
EVX-01Phase 2Melanoma Stage IV
DecadronPhase 3Malignant Neoplasms of Male Genital Organs
PembroRTPhase 2Non-small Cell Lung Cancer, NSCLC
Brexucabtagene autoleucel (other names: brexu-cel, Tecartus)Phase 2Recurrent Mantle Cell Lymphoma
MK1903Phase 2Dyslipidemia
MK-2206Phase 2PANCREAS
ElbasvirPhase 3Hepatitis C
Peginterferon alfa-2a (Peg-IFN)Phase 2Hepatitis C, Chronic
ANV600Phase 2Advanced Solid Tumor
SevofluranePhase 3Muscle Relaxation
HIBERIX™Phase 3Pneumococcal Infections
Pembrolizumab/FavezelimabPhase 2Colorectal Cancer
Pentacel™Phase 3Pneumococcal Infections
Pembrolizumab (for 30 minutesPhase 2Breast Cancer
M-M-R™ IIPhase 3Pneumococcal Infections
Ritonavir-boosted protease inhibitorPhase 2HIV
Uprifosbuvir (+) Grazoprevir (+) RuzasvirPhase 2Hepatitis C
Price & technical context
3-month
-5.5%
6-month
+26.0%
12-month
+54.9%
52-wk range
$92.86–$156.45
vs 50-day MA
-1.4%
vs 200-day MA
+11.6%
Realized vol
29.6%
Max drawdown
-31.1%

Daily closes through 2026-11-17. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for MRK (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.